Alzheimer’s disease serves as bookends to Brent Vaughan’s career so far. Twenty years ago, he worked for a Bay Area biotech whose pipeline included small molecules in development for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback